The Portuguese Institute of Oncology (IPO-Porto) is a CHKS, JACIE and ISO 9001: 2008-accredited institution devoted to cancer treatment, research and education. It’s a part of the National Health Service and an OECI Comprehensive Cancer Centre, recognised as a National Reference Centre. It’s a healthcare provider for paediatric oncology, oesophageal, hepatobiliary, rectal, testicular and pancreatic cancer, cutaneous, soft tissue and bone sarcomas.
Moreover, it’s a member of ERN EuroBloodNet; ERN Genturis; ERN eUROGEN; ERN EURACAN and ERN PAEDCAN, as well as the European Infrastructure for Translational Medicine, and has an Early Phase Clinical Trials Unit – Centre for Innovative Therapeutics in Oncology.
The Radiation Oncology Service hosts two CT scanners and one 3T MRI with access to PET-CT, and 9 linear accelerators, with loop mobile imaging (CBCT), dedicated to intraoperative radiotherapy, and a Brachytherapy Unit (LDR/HDR).
This equipment enables IPO-Porto to treat 5,000 new patients a year.
Get more information about the IPO Porto at: www.ipoporto.pt








